Ann Arbor-based Adeona Pharmaceuticals Inc. (NYSE Amex: AEN) said Thursday that it had received shareholder approval to change its corporate name to Synthetic Biologics Inc.
The latest staffing, boardroom and leadership changes at Michigan’s technology-focused companies and institutions
Adeona Pharmaceuticals Inc. has swapped bosses as it continues testing new drugs for multiple sclerosis, fibromyalgia and Lou Gehrig’s disease. It’s also considering a new business focus and a name change.
Pharma startup Adeona and its research partner report no safety issues related to high doses of zinc to slow the effects of Lou Gehrig’s Disease
The latest personnel, leadership and boardroom news from Michigan’s technology-focused companies and institutions
Adeona Pharmaceuticals Inc. (NYSE: AEN), announced Thursday that Chardan Capital Markets initiated independent equity research coverage of the company with a “Buy” rating and a 12-month price target of $1 per share.
The latest personnel and boardroom announcements from Michigan’s technology-focused companies and institutions
Ann Arbor-based Adeona Pharmaceuticals Inc. (AMEX: AEN), a developer of medicines for serious central nervous system diseases, Monday reported its second quarter financial results for the period ended June 30, as well as updates since the beginning of the second quarter.
Ann Arbor-based Adeona Pharmaceuticals Inc. said it will commercialize an oral zinc lozenge as a homeopathic over-the-counter treatment for the common cold under the brand name wellZin.
Ann Arbor-based Adeona Pharmaceuticals Inc. (NYSE Amex: AEN) announced Thursday that it has expanded its pipeline of proprietary zinc-based therapies to include a planned Phase IIb clinical trial of patients suffering from amyotrophic lateral sclerosis also known as Lou Gehrig’s Disease.